|
Preferred term
|
Phase Ib N (%)
|
Phase II N (%)
|
|---|
| |
(n=42)
|
Fruquintinib group (n=47)
|
Placebo group (n=24)
|
|---|
|
Hypertension
|
9 (21.4)
|
14 (29.8)
|
0
|
|
HFSR
|
4 (9.5)
|
7 (14.9)
|
0
|
|
Diarrhea
|
4 (9.5)
|
1 (2.1)
|
0
|
|
Serum sodium decreased
|
3 (7.1)
|
0
|
0
|
|
Fatigue
|
2 (4.8)
|
2 (4.3)
|
0
|
|
Chest pain
|
2 (4.8)
|
0
|
0
|
|
Blood bilirubin increased
|
1 (2.4)
|
2 (4.2)
|
1 (4.2)
|
|
AST increased
|
0
|
1 (2.1)
|
1 (4.2)
|
|
Platelet count decreased
|
0
|
1 (2.1)
|
1 (4.2)
|
|
Blood alkaline phosphatase increased
|
0
|
0
|
2 (8.3)
|
|
Myalgia
|
0
|
0
|
1 (4.2)
|
|
Coma hepatic
|
0
|
0
|
1 (4.2)
|
|
Infection
|
0
|
0
|
1 (4.2)
|
-
TEAE treatment-emergent adverse event, HFSR hand-foot skin reaction, AST aspartate aminotransferase
